Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02293395 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 3,037
- Enrollment target
NCT02293395 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 3,037 participants.
The verdict
NCT02293395, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3,037 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate the risk of bleeding with rivaroxaban, compared with acetylsalicylic acid (ASA), in addition to a single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12 inhibitor agent: clopidogrel or ticagrelor), in participants with a recent acute coronary syndrome (ACS: including ST segment elevation myocardial infarction \[STEMI\] and non-ST-segment elevation acute coronary syndrome \[NSTE-ACS\]).
Interventions
- DRUG Clopidogrel
- DRUG Rivaroxaban
- DRUG Ticagrelor
- DRUG Acetylsalicylic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,037 participants |
| Start Date | 2015-04-20 |
| Est. Completion | 2016-10-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02293395
The ClinicalTrials.gov registry entry for NCT02293395 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3,037 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Clopidogrel is the first listed.
NCT02293395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02293395 about?
NCT02293395 is a clinical study titled "A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome". The purpose of this study is to estimate the risk of bleeding with rivaroxaban, compared with acetylsalicylic acid (ASA), in addition to a single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12 inhibitor agent: clopidogrel or ticagrelor), in participants with a recent a...
What is the current status of trial NCT02293395?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3,037 participants. The study started on 2015-04-20. Estimated completion is 2016-10-14.
What interventions are being tested in trial NCT02293395?
The interventions under investigation include: Clopidogrel (DRUG), Rivaroxaban (DRUG), Ticagrelor (DRUG), Acetylsalicylic acid (DRUG).
Who is sponsoring clinical trial NCT02293395?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.